The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research ...

Experts warn the strange side effect could lead to delayed diagnoses and treatments, as well as unnecessary medical ...

Biomea Fusion shares spiked on positive 52-week Phase II data for icovamenib in type 2 diabetes. Read why I rate BMEA stock a ...

Skye Bioscience's nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when ...

High costs and shortages are driving demand for unregulated GLP-1 drugs, prompting FDA alerts about counterfeit Ozempic and ...

GLP-1 receptor agonists lead a new wave of therapeutic options that may benefit patients with osteoarthritis, according to ...

Biomea Fusion's experimental drug showed sustained blood sugar control in patients with type 2 diabetes and may benefit those not responding to GLP-1 therapies like Novo Nordisk's Ozempic, it said on ...

At its pharmacy, Costco now offers Ozempic and Wegovy at huge discounts, but are these GLP-1 drugs right for you?

Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug ...

Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

This 3-part series looks at the current evidence for the treatment of SUDs. Part 2 reviews the use of GLP-1 receptor agonists and alcohol use disorder.

Patients prescribed glucagon-like peptide-1 receptor agonists have roughly half the risk of developing noninfectious uveitis.